Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04115306 · ClinicalTrials.gov registry record · Phase 1

Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer

A Phase 1 study of Metastatic Breast Cancer, sponsored by Phoenix Molecular Designs.

Recruiting
Registry status
Phase 1
Development phase
61
Enrollment target
11
Study locations

NCT04115306 is a Phase 1 study of Metastatic Breast Cancer that is actively recruiting participants, run by Phoenix Molecular Designs. The registered enrollment target is 61 participants, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (70% lower). The trial reports 11 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04115306, a Phase 1 study of Metastatic Breast Cancer, is actively recruiting participants, sponsored by Phoenix Molecular Designs.

RECRUITING
Registry status
Phase 1
Development phase
61 participants
Enrollment target
11
Study locations

Study Summary

The purpose of this study is to test the safety and tolerability of PMD-026 in patients with metastatic breast cancer. PMD-026 is a targeted oral agent designed to kill tumor cells in metastatic breast cancer.

Conditions Studied

Metastatic Breast Cancer

Interventions

  • DRUG PMD-026
  • DRUG fulvestrant

Study Locations (11)

California

  • City of Hope - Duarte
  • City of Hope Orange County, Lennar - Irvine
  • University of California, Los Angeles (UCLA) - Los Angeles

Texas

  • Oncology Consultants - Houston
  • South Texas Accelerated Research Therapeutics - San Antonio

Arizona

  • Banner MD Anderson Cancer Center - Gilbert

Florida

  • Moffitt Cancer Center - Tampa

Illinois

  • City of Hope Chicago - Zion

Massachusetts

  • Massachusetts General Hospital Cancer Center - Boston

Michigan

  • Profound Research - Farmington Hills

Ohio

  • Ohio State University - Columbus

Trial Details

FieldValue
Enrollment Target 61 participants
Start Date 2019-11-14
Est. Completion 2026-10
Phase Phase 1

Sponsor

Phoenix Molecular Designs

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04115306

The ClinicalTrials.gov registry entry for NCT04115306 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (70% lower). The listed sponsor is Phoenix Molecular Designs, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which PMD-026 is the first listed.

NCT04115306 reports 11 study locations spanning 8 distinct geographic areas - top geographies include California, Texas, Arizona.

Frequently Asked Questions

What is clinical trial NCT04115306 about?

NCT04115306 is a clinical study titled "Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer". The purpose of this study is to test the safety and tolerability of PMD-026 in patients with metastatic breast cancer. PMD-026 is a targeted oral agent designed to kill tumor cells in metastatic breast cancer.

What is the current status of trial NCT04115306?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2019-11-14. Estimated completion is 2026-10.

What conditions does trial NCT04115306 study?

This clinical trial studies the following conditions: Metastatic Breast Cancer.

What interventions are being tested in trial NCT04115306?

The interventions under investigation include: PMD-026 (DRUG), fulvestrant (DRUG).

Who is sponsoring clinical trial NCT04115306?

This trial is sponsored by Phoenix Molecular Designs, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04115306 being conducted?

This trial has 11 study locations across Arizona, California, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Breast Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.